NeuroCytotron in the Treatment of Autism Spectrum Disorder

Inclusion Criteria:

1. Male or female subjects with a confirmed diagnosis of ASD according to DSM-5criteria.

2. Subjects ≥ 3 and ≤ 50 years.

3. Subjects with ASD severity grade 1 to 3 according to DSM-5 criteria.

4. To have the informed consent of the parents or legal representatives for thesubject's participation in the study.

5. Subjects must be physically able and willing to undergo the treatment sessions.

6. Subjects must be medically and psychologically stable to participate in the study.

Exclusion Criteria:

1. Presence of medical conditions that could contraindicate the use of NeuroCytotronDM, such as severe neurological disorders and difficult-to-control epilepsy.

2. uncontrolled epilepsy is defined as: more than 1 generalized seizure in anymonth within the 3 months prior to the day 1 visit, or

3. history of any of the following within 9 months prior to the day 1 visit:prolonged seizures or repetitive seizure activity requiring administration of arescue benzodiazepine (oral, rectal, etc.) more than once a month, seizureslasting more than 10 minutes, status epilepticus or epilepsy with autonomicinvolvement.

4. Concurrent participation in other therapies or interventions for autism during thestudy period.

5. Logistical or situational limitations that prevent regular attendance at treatmentsessions.

6. History of significant adverse reactions to similar treatments or involving the useof anesthesia.

7. Presence of serious behavioral problems or aggression that may affect the safety ofthe subject or staff during treatment sessions.

8. Current or recent (previous 14 days) history of clinically significant bacterial,fungal, viral or mycobacterial infection.

9. Subjects with magnetic implants, pacemakers, claustrophobia or any other conditionthat prevents them from entering or remaining in the DM NeuroCytotron.